Amdocs (DOX) Reports Q3 Earnings: What Key Metrics Have to Say

Amdocs (DOX) reported Q3 2025 revenue of $1.14 billion, an 8.5% year-over-year decline, yet it surpassed the Zacks Consensus Estimate by 1.37%. EPS increased to $1.72 from $1.62 a year ago, also beating estimates. While North America and Rest of World revenues declined, European revenue grew 7.7% and Managed Services revenue rose 4.1%, exceeding analyst expectations. Shares have underperformed the S&P 500 over the past month, falling 8.5%, and the stock holds a Zacks Rank #3 (Hold).

Analysis

Amdocs (DOX) presented a mixed financial picture for its third quarter ending June 2025, characterized by a significant year-over-year revenue decline but resilient profitability and pockets of regional and operational strength. Total revenue contracted by 8.5% to $1.14 billion, a notable top-line deterioration. However, this figure surpassed the Zacks Consensus Estimate by 1.37%, and more importantly, EPS grew from $1.62 to $1.72, narrowly beating analyst expectations by 0.58%. A deeper look at the key metrics reveals a sharp divergence in performance. The company's largest market, North America, experienced a 10.1% revenue decline, while the 'Rest of the world' segment fell 14.6%, missing its estimate. In stark contrast, European revenue grew a robust 7.7% to $189.4 million, substantially outperforming forecasts. Similarly, Managed Services revenue proved to be a key support, growing 4.1% to $771.5 million and beating estimates. The market has reacted negatively to the headline revenue weakness, with the stock underperforming the S&P 500 composite by 900 basis points over the past month (-8.5% vs +0.5%), aligning with the neutral Zacks Rank #3 (Hold) rating.

Key Decisions for Investors

• Investors should scrutinize whether the outperformance in Europe and Managed Services is sustainable and can eventually offset the significant, ongoing revenue decline in the core North American market.
• Given the stock's recent -8.5% underperformance, value-oriented investors might see an entry point, but should remain cautious until there is clear evidence of stabilization or a turnaround in the North American segment.
• The conflicting signals of declining revenue versus growing EPS warrant a neutral stance; holding existing positions may be prudent, but adding exposure carries risk until the company provides improved guidance for its weaker geographic segments.